Kopran Ltd.

₹127.33

-2.9 (-2.2%)

KOPRAN Share Price

Pharmaceuticals & Biotechnology

As on January 29, 2026

SectorHealthcare

IndustryPharmaceuticals & Biotechnology

Basic IndustryPharmaceuticals

Market Cap₹ 626 Cr

P/E Ratio15.95

Dividend Yield0.24 %

Trendline Performance

Unlock Stock of the Month

T&C*

Technicals

Indicators	Value	Signal
5-DMA	130.54	Bearish
10-DMA	135.79	Bearish
20-DMA	143.31	Bearish
50-DMA	138.81	Bearish
100-DMA	154.2	Bearish
200-DMA	167.26	Bearish

Historical Performance

1 Year

-32.5%

3 Years

-5.2%

5 Years

12.3%

10 Years

119.7%

Shareholding Pattern

Values Analysis

Loading chart...

Profit & Loss

Below figures are in Rs. Crores

Particulars	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Net Sales	6,296	6,146	5,510	4,775	4,918
Total Expenditure	5,567	5,402	4,992	3,903	4,102
Other Income	40	147	31	108	182
Operating Profit	769	890	549	980	998
Interest	93	86	61	51	62
Depreciation	156	129	127	111	102
Profit Before Tax	519	675	361	818	833
Consolidated Net Profit	386	510	272	610	616
Adjusted EPS	8	11	6	13	14

Compounded Sales Growth

10 Years:16.3

5 Years:11.9

3 Years:5.7

TTM:0.5

Compounded Profit Growth

10 Years:29.2

5 Years:12.9

3 Years:-8.8

TTM:-5.4

Stock Price CAGR

10 Years:8.2

5 Years:2.4

3 Years:-0.6

TTM:-32.1

Return on Equity

10 Years:2.5

5 Years:14.2

3 Years:5.6

last year:8

Quarterly Results

Below figures are in Rs. Crores

Particulars	Sep-2024	Dec-2024	Mar-2025	Jul-2025	Sep-2025
Sales	1,70,754	1,35,936	1,28,552	1,22,189	1,05,161
Expenses	63,042	56,557	52,457	45,459	34,856
Operating Profit	1,07,712	79,379	76,096	76,730	70,304
OPM %	63%	58%	59%	63%	67%
Other Income	33,912	31,759	27,333	24,879	18,947
Interest	77,780	58,584	59,248	62,137	53,713
Depreciation	2,345	1,681	1,385	1,277	1,221
Profit Before Tax	61,498	50,873	42,796	38,195	34,318
Tax %	25%	25%	26%	29%	35%
Net Profit	46,149	38,151	31,857	27,296	22,446
EPS in Rs	83	69	58	50	42

Balance Sheet

Below figures are in Rs. Crores

Particulars	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Share Capital	483	482	482	482	433
Total Reserves	4,684	4,420	3,910	3,780	2,018
Long-Term Borrowings	---	---	---	---	---
Total Non-Current Liabilities	367	335	335	331	337
Other Current Liabilities	389	228	328	314	289
Short Term Borrowings	1,291	810	555	537	431
Total Liabilities	8,440	7,432	6,497	6,109	4,394
Capital Work in Progress	994	777	557	275	371
Long Term Loans & Advances	110	91	143	82	61
Currents Investments	---	---	---	---	---
Short Term Loans and Advances	945	827	875	756	441
Total Current Assets	5,097	4,540	3,991	4,149	2,769
Total Assets	8,440	7,432	6,497	6,109	4,394
Adjusted Book Value	107	102	91	88	57

Positive

(80 to 100)

Neutral

(60 to 79)

Negative

(0 to 59)

The stock has a moderate PE of 15.95, suggesting fair valuation relative to earnings.
Over the last three years, the stock delivered a weak 3-year price CAGR of -0.6%, indicating poor shareholder returns.
The stock carries a high beta of 1.3, implying higher volatility and elevated risk.
In the last financial year, the company reported an EBITDA of ₹769 million, reflecting positive operating performance.
In the previous financial year, the company generated revenue of ₹6296 million, suggesting a mid-sized operation.

Investment Calculator

Investment Amount:

₹

Investment Amount: ₹ 1000000

Current Value: ₹ 679238.2

No. of Shares: 5334 (Approx)

Performance:-32.1%

P/L: ₹-320761.8

NIFTY Performance: 9.3%

1 day Top Gainers